Physician profile
Bethany Schmidt
NPI 1669488433
$6,633.19
in general payments reported to CMS, 2019-2025
12 companies · $1,970 in 2025
The $1,970 reported for 2025 was more than what 99% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $487 · 2022: $1,124 · 2023: $1,312 · 2024: $1,739 · 2025: $1,970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,021.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,550.97 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,119.05 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $796.05 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $697.54 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $677.91 | 2021-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $390.46 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $198.08 | 2024-2025 | Rezdiffra, Resmetirom |
| Organon LLC | $109.43 | 2023-2025 | Hadlima, Renflexis |
| Regeneron Healthcare Solutions, INC. | $49.96 | 2023 | Dupixent |
| Merck Sharp & Dohme LLC | $16.66 | 2023 | Dificid |
| Braintree Laboratories, INC. | $13.56 | 2025 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $13.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.